Report cover image

Breakthrough Therapy Designation Market Growth, Size, Trends Analysis - By Application, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published Apr 25, 2025
Length 244 Pages
SKU # SPER20068075

Description

Breakthrough Therapy Designation Market Introduction and Overview

According to SPER market research, ‘Global Breakthrough Therapy Designation Market Size- By Application, By End User – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Breakthrough Therapy Designation Market is predicted to reach 431.11 billion by 2034 with a CAGR of 14.48%.

The FDA’s Breakthrough Therapy Designation program is intended to speed up the development and evaluation of medications for serious or life-threatening illnesses. The medicine must provide a significant improvement over current therapy on important endpoints, according to preliminary clinical evidence, in order to qualify. Rolling review, extensive FDA advice, and possible priority review for clearance are some advantages of this category.

Restraints:

A major obstacle to receiving Breakthrough Therapy (BT) classification is high development costs, since BT frequently necessitates enormous resources, cutting-edge technologies, and long clinical studies. Smaller pharmaceutical companies may find it difficult to compete with larger players in the market due to the financial burden these charges might cause. This financial strain may potentially impede the expansion of the market by delaying the research and approval of treatments.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered

By Application, By End User

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer, Inc, AbbVie, Inc, Bristol-Myers Squibb Company, Gilead Sciences, Inc, Sanofi, Regeneron Pharmaceuticals Inc, AstraZeneca, Boehringer Ingelheim GmbH.

Global Breakthrough Therapy Designation Market Segmentation:

By Application:

Based on the Application, GlobalBreakthrough Therapy Designation Market is segmented as; Oncology, InfectiousDiseases, Rare Diseases, Autoimmune Diseases, Pulmonary Diseases, NeurologicalDisorders.

By End User:

Based on the End User, GlobalBreakthrough Therapy Designation Market is segmented as; Hospitals, Clinics,Research Institutes, Laboratories.

By Region:

This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East& Africa.

Table of Contents

244 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Breakthrough Therapy Designation Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Breakthrough Therapy Designation Market
7. Global Breakthrough Therapy Designation Market, By Application 2021-2034 (USD Million)
7.1. Oncology
7.2. Infectious Diseases
7.3. Rare Diseases
7.4. Autoimmune Diseases
7.5. Pulmonary Diseases
7.6. Neurological Disorders
8. Global Breakthrough Therapy Designation Market, By End User 2021-2034 (USD Million)
8.1. Hospitals
8.2. Clinics
8.3. Research Institutes
8.4. Laboratories
9. Global Breakthrough Therapy Designation Market, 2021-2034 (USD Million)
9.1. Global Breakthrough Therapy Designation Market Size and Market Share
10. Global Breakthrough Therapy Designation Market, By Region, 2021-2034 (USD Million)
10.1. Asia-Pacific
10.1.1. Australia
10.1.2. China
10.1.3. India
10.1.4. Japan
10.1.5. South Korea
10.1.6. Rest of Asia-Pacific
10.2. Europe
10.2.1. France
10.2.2. Germany
10.2.3. Italy
10.2.4. Spain
10.2.5. United Kingdom
10.2.6. Rest of Europe
10.3. Middle East and Africa
10.3.1. Kingdom of Saudi Arabia
10.3.2. United Arab Emirates
10.3.3. Qatar
10.3.4. South Africa
10.3.5. Egypt
10.3.6. Morocco
10.3.7. Nigeria
10.3.8. Rest of Middle-East and Africa
10.4. North America
10.4.1. Canada
10.4.2. Mexico
10.4.3. United States
10.5. Latin America
10.5.1. Argentina
10.5.2. Brazil
10.5.3. Rest of Latin America
11. Company Profile
11.1. AbbiVie, Inc.
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. AstraZeneca
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Boehringer Ingelheim International GmbH.
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Bristol-Myers Squibb Company
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. F. Hoffmann-La Roche Ltd.
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Gilead Sciences, Inc.
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. Novartis AG
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. Pfizer, Inc.
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. Regeneron Pharmaceuticals Inc.
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. Sanofi
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Others
12. Conclusion
13. List of Abbreviations
14. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us